Literature DB >> 23654101

[Effects of oleic acid on expression of adiponectin and its PPARgamma mechanism in 3T3-L1 adipocytes].

Wei Luo1, Jieyi Lin, Yi Zhang, Jingyi Ouyang, Limei Mao.   

Abstract

OBJECTIVE: To explore the effects of oleic acid on the gene and protein expression of adiponectin and its PPARgamma mechanism in 3T3-l1 adipocytes.
METHOD: L1 adipocytes were incubated with different concentration (25, 50, 100, 200, 400 micromol/L) for 24h, and the mRNA expression of adiponectin and PPARgamma was determined by real-time PCR (relative quantity). And then the 3T3-L1 adipocytes were treated for OA at concentration of 100 micromol/L for 24h with/without the affect of PPARgamma inhibitor GW9662, to determine the gene and protein expression of adiponectin. The protein expression changes of adiponectin were detected by immunoblotting. RESULT: The mRNA expression of adiponectin and PPARgamma increased at the dosages of 25, 50, and 100micromol /L. With the increase of OA, the mRNA expression of adiponectin and PPARgamma decreased in a dose-dependent manner. Incubating with GW9662 and OA, decreases in the mRNA and protein expression of adiponectin were 77% and 78.01% (P < 0.05), compared with the control respectively.
CONCLUSION: OA could increase the gene expression of adiponectin and PPARgamma mRNA in dose-dependent manner in 3T3-L1 adipocytes,which could be specifically blocked by GW9662, OA indues the expression of adiponectin mRNA and protein in 3T3-L1 adipocytes, possibly by a mechanism involving PPARgamma.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23654101

Source DB:  PubMed          Journal:  Wei Sheng Yan Jiu        ISSN: 1000-8020


  1 in total

1.  Positive Effects of Extra-Virgin Olive Oil Supplementation and DietBra on Inflammation and Glycemic Profiles in Adults With Type 2 Diabetes and Class II/III Obesity: A Randomized Clinical Trial.

Authors:  Erika Aparecida Silveira; Lorena Pereira de Souza Rosa; Danilo Pires de Resende; Ana Paula Dos Santos Rodrigues; Adeliane Castro da Costa; Andréa Toledo de Oliveira Rezende; Matias Noll; Cesar de Oliveira; Ana Paula Junqueira-Kipnis
Journal:  Front Endocrinol (Lausanne)       Date:  2022-05-02       Impact factor: 6.055

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.